Compounded Semaglutide in 2026: Is It Legal and Safe?

Few topics generate as much confusion as compounded semaglutide and compounded tirzepatide. Between 2022 and 2025, shortages of branded weight loss pens led to a boom in compounded versions sold by pharmacies and telehealth companies, often at lower prices. Then the shortages officially ended, regulators tightened the rules and many patients were left wondering whether compounded products are still legal, whether they are safe and how they differ from brand-name Wegovy, Ozempic, Mounjaro and Zepbound. This 2026 guide explains the rules in plain language, the safety concerns and the questions to ask before you accept any compounded pen.

This is general information, not legal or medical advice. The rules differ by country, and regulators change guidance, so confirm the current position with a licensed pharmacist or your national authority.

In This Guide

• What Is Compounded Semaglutide or Tirzepatide?
• Is Compounded Semaglutide Legal in 2026?
• Safety Concerns With Compounded Versions
• Compounded vs Brand-Name: Key Differences
• Questions to Ask Before Accepting a Compounded Product
• Red Flags in Marketing
• What Safer Alternatives Exist?
• If You Already Use a Compounded Product

What Is Compounded Semaglutide or Tirzepatide?

Compounding is the practice of a pharmacist preparing a customised medicine for an individual patient when a commercially available product does not meet that patient’s needs. Compounded drugs are not FDA-approved: the agency does not review them for safety, effectiveness or quality before they are sold. In the United States, compounding is lawful in defined circumstances under sections 503A (state-licensed pharmacies preparing medicines for identified patients) and 503B (outsourcing facilities) of the Federal Food, Drug, and Cosmetic Act.

During a declared drug shortage, the FDA allows compounders to make copies of the scarce drug more freely. When the shortage ends, that flexibility largely disappears. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, followed by transition periods after which mass-produced copies were expected to stop. Compounders may still prepare products when there is a documented clinical need for a change from the approved drug, such as an allergy to an inactive ingredient, but the bar is higher.

Is Compounded Semaglutide Legal in 2026?

In the USA, the legal space for compounded semaglutide and tirzepatide is now narrow. Pharmacies cannot simply copy the commercial product at scale. Individualised preparation based on a prescriber’s documented medical need for a change may still be allowed, but regulators are scrutinising marketing claims and ingredients. State boards of pharmacy also have their own rules. The FDA has issued warning letters to firms selling unapproved or misbranded versions and has warned about counterfeit products. You can follow regulatory updates on the FDA drugs pages.

In the UK and EU, the situation is stricter. Medicines must be authorised, and compounding of semaglutide or tirzepatide from bulk substances is generally not permitted as a substitute for authorised products. Canada, Australia and many Latin American countries also limit compounding of patented medicines. If a seller outside the USA claims to offer “custom compounded Mounjaro,” treat it with great caution and read our region guides for the UK, Canada and Europe.

Safety Concerns With Compounded Versions

• No FDA approval or standardised testing. Potency and purity can vary between batches and pharmacies.
• Salt forms. Some compounders have used semaglutide sodium or semaglutide acetate instead of the base form in approved drugs. These salt forms have not been shown to be safe and effective.
• Dosing errors. Vials with syringes require patients to draw up the dose in units or milligrams. Dosing mistakes have caused overdoses and hospital visits, with symptoms such as severe vomiting, fainting and low blood sugar.
• Additives. Some products include vitamins such as B12 or glycine. These additions have no proven benefit in weight loss and are not part of the approved drug.
• Contamination and storage. Poor sterile technique or storage can lead to infections or degraded medicine.
• Counterfeits and illegal imports. Websites selling “research” semaglutide or tirzepatide labelled “not for human consumption” are not legitimate medical suppliers.

Read our article on whether it is legal to buy research peptides to understand why products labelled for laboratory use should never be injected by patients without clinical oversight.

Compounded vs Brand-Name: Key Differences

Factor	Brand-name pen	Compounded product
Regulatory approval	Approved after clinical trials and manufacturing inspection	Not approved; made for an individual patient
Evidence	Large randomised trials	No product-specific trials
Dose delivery	Pre-set pen	Vial and syringe or varied devices
Consistency	High, tightly controlled	Varies by pharmacy and batch
Labelling	Standardised leaflet	Pharmacy-specific label
Cost	Often higher	Sometimes lower, but not always

Clinical results such as roughly 15 percent average weight loss with semaglutide 2.4 mg in STEP 1, or 15 to 21 percent with tirzepatide in SURMOUNT-1, come from the approved products. Those figures cannot be assumed for a compounded copy. See our trial data review for the evidence.

Questions to Ask Before Accepting a Compounded Product

1. Which licensed pharmacy prepares it, and in which state or country?
2. Is it a 503A pharmacy or a 503B outsourcing facility?
3. What active ingredient form is used: base or salt?
4. Why is a compounded version medically necessary for me instead of the approved pen?
5. Can I see a certificate of analysis or third-party testing?
6. How will I measure and inject my dose, and who will teach me?
7. What is the beyond-use date and storage requirement?
8. Who do I contact if I have side effects?

If answers are vague, defensive or missing, choose another provider.

Red Flags in Marketing

• “Same as Ozempic” or “generic Mounjaro” claims. There is no US-approved generic of these products at the time of writing.
• Use of brand names or logos implying approval.
• Guaranteed weight loss claims.
• Pricing that appears too good to be true.
• No physician review, or approval based only on a quiz.
• Products shipped without cold-chain information.

What Safer Alternatives Exist?

If cost is the barrier, there are legitimate options. Manufacturers and telehealth providers offer self-pay programmes for approved pens at reduced prices for some doses. Insurers sometimes cover the medicine for type 2 diabetes, and cost assistance programmes may help eligible patients. Lifestyle programmes and other approved medicines, including orlistat and naltrexone-bupropion, are cheaper alternatives to discuss with your prescriber; see our Mysimba guide. For help comparing prices and coverage, read how much weight loss injections cost.

If You Already Use a Compounded Product

Do not panic or stop abruptly without advice. Talk to your prescriber about your supply, dose and plan. Ask whether you should transition to an approved pen and how to convert the dose, because units on a syringe are not the same as milligrams on a pen. Check how you store the vial, discard it after the beyond-use date and never share syringes. Report adverse reactions to your prescriber and to the FDA MedWatch programme. Keep records of lot numbers and the pharmacy name.

At Weight Lose Solution, prescription treatments are dispensed after an online assessment and approval by a licensed physician. If you want to discuss approved options, contact our team, or read the safe buying guide.

How Regulators Around the World Treat Compounded Semaglutide

Regulators have responded to the popularity of compounded semaglutide in different ways. In the United States the FDA has published lists of drugs in shortage, issued warnings about dosing errors, adverse event reports and unapproved ingredients, and sent letters to companies using misleading marketing. State boards of pharmacy oversee licensed compounding pharmacies, and professional associations have urged caution. In the United Kingdom, the MHRA has warned about fake weight loss pens and unlicensed products sold online, and the General Pharmaceutical Council expects pharmacies to supply only authorised or properly justified medicines. In the European Union, national authorities enforce the principle that authorised medicines should be used when available, and online sales of unauthorised GLP-1 products have been the subject of alerts. Because laws differ, never assume that a product sold in one country is lawful in another.

What Doctors Say About Compounded Semaglutide

Many obesity medicine specialists advise using approved products whenever possible because dose accuracy, purity and evidence are known. Some clinicians accepted compounded versions during shortages as a pragmatic choice for patients who could not otherwise access treatment, but few recommend them now when approved pens are available. Where a patient has a documented clinical reason, such as an allergy to an excipient, a prescriber and compounding pharmacist may agree an individualised plan with careful dosing instructions. The key principle is that a licensed clinician takes responsibility for assessing you, choosing the product and monitoring your response. Beware of any service that treats compounded semaglutide as a lifestyle subscription without that clinical oversight.

Practical Steps to Protect Yourself

Write down the pharmacy name, product name, strength, lot number and expiry date from your label. Store the vial as directed, usually in the fridge. Use a new sterile syringe each time, and keep a dosing log. Learn the difference between milligrams and units, and ask your pharmacist to confirm the dose in writing. If you ever feel faint, sweaty, confused or extremely sick after an injection, seek emergency help immediately. Whether you choose a brand-name pen or a compounded product, regular check-ins with a qualified clinician are the best protection.

Key Takeaways on Compounded Products

Approved pens have known strength, purity and evidence. Compounded versions do not carry that assurance, and the legal space for them has narrowed since the shortages ended. Ask direct questions about the pharmacy, the ingredient form and your clinical need, and be cautious about marketing that promises brand-level results at a fraction of the cost. If you use a compounded product, learn exactly how to measure the dose, store the vial and report problems. Whenever possible, work with a licensed prescriber to move to an approved product.

Editorial Standards and Sources

This guide was prepared by the Weight Lose Solution clinical content team. Medicine information is checked against official product labels and published trial data, and we update articles when guidance changes. It is educational only: prescription treatments are dispensed after an online assessment and approval by a licensed physician, and your own prescriber always takes priority.

Key sources used across our guides:

• Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
• Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
• U.S. Food and Drug Administration drug information and approved product labelling.
• World Health Organization obesity and overweight fact sheet.

Related Guides and Next Steps

Continue your research with these related guides from our clinical content team:

• Who should not take GLP-1 medicines
• Buying weight loss injections in South America
• How to inject a weight loss pen step by step
• What to do after a missed dose
• Breaking a weight loss plateau on GLP-1
• How GLP-1 injections work
• Wegovy side effects
• Browse prescription weight loss medications

Frequently Asked Questions About Compounded semaglutide

Medical disclaimer: this article is for general education and is not medical advice. Prescription treatments are dispensed only after an online health assessment and approval by a licensed physician. Always follow the guidance of your own prescriber and the patient information leaflet.